Erik Sjögren, Assoc. Prof., Ph.D.

Principal Consultant & PBPK/PBBM Platform Scientific Lead

Portrait-of-Erik-Sjogren_Pharmetheus-2

Bio

  • Joined Pharmetheus in 2017, actively working in client projects, serving as PBPK/PBBM Platform Scientific Lead
  • Expertise includes physiological based pharmacokinetic and biopharmaceutics modeling and simulation, clinical pharmacology, and pediatrics across therapeutic areas
  • Experience as Researcher at Uppsala University, Sweden, where he has a part-time position to perform research and supervise Ph.D. students. Previously, he worked as Acting Senior Lecturer at Uppsala University, Sweden and Postdoctoral Researcher at AstraZeneca Mölndal, Sweden
  • M.Sc. in Pharmaceutical Sciences (2004), Ph.D. in Pharmaceutical Sciences (2010), Associate Professor in Biopharmaceutics (2016) from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Physiologically based pharmacokinetic modelling to support the development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis: An MIDD case studyA quantitative systems pharmacology framework of immunogenicity to propose mitigation strategies after subcutaneous administrationOptimizing Formulations for Treatment of Cryptococcal Meningoencephalitis in Sub-Saharan HIV Patients: Insights from PBPK ModelingPBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular spaceBioavailability of a novel sustained-release pellet formulation of 5-flucytosine in healthy-fed participants for use in patients with cryptococcal meningitisSkin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South AsiaPhysiologically based pharmacokinetic modelling to support design of microarray patches delivering antiretroviral drugs to HIV positive children.Absorption, Bioavailability, and Immunogenicity after Subcutaneous Administration: Evaluation of a Subcutaneous Platform within the Open Systems Pharmacology frameworkPhysiologically-based pharmacokinetic (PBPK) modeling to predict disease effects on 5-flucytosine pharmacokinetics (PK) in the context of a switch from an immediate release (IR) to a sustained release (SR) formulation.Development of a PBPK model to predict monoclonal antibody pharmacokinetics and bioavailability following subcutaneous administrationPredicting disease effect on the pharmacokinetics (PK) of sustained and immediate release formulations by applying physiologically based pharmacokinetic (PBPK) modelling